Brian R. Edlin, M.D.

• Research
• Honors & Awards
• Biography
• Publications

Publications

Selected original articles:

1. Uccellini L, Tseng FC, Monaco A, Shebl FM, Pfeiffer R, Dotrang M, Buckett D, Busch MP, Wang E, Edlin BR, Marincola F, O'Brien TR. Hepatitis C virus RNA levels in a multi-ethnic cohort of injection drug users: human genetic, viral and demographic associations. Hepatology. In press.
2. Raghuraman S, Park H, Osburn WO, Winkelstein E, Edlin BR, Rehermann B. Spontaneous clearance of chronic hepatitis C virus infection is associated with appearance of neutralizing antibodies and reversal of T cell exhaustion. J Infect Dis 2012;205:763–71.
3. Shebl FM, Pfeiffer RM, Edlin BR, Muchmore B, Buckett D, Chen S, Dotrang M, Prokunina-Olsson L, O'Brien TR. IL28B rs12979860 genotype and spontaneous clearance of hepatitis C virus in a multi-ethnic cohort of injection drug users: evidence for a supra-additive association. J Infect Dis 2011;204:1843-7.

4. Telles Dias P, Hahn JA, Delwart E, Edlin BR, Martin J, Lum P, Evans J, Kral A, Deeks S, Busch MP, Page K. Temporal changes in HCV genotype distribution in three different high risk populations in San Francisco, California. BMC Infect Dis 2011;11:208.

5. Zeremski M, Hooker G, Shu MA, Winkelstein E, Brown Q, Des Jarlais DC, Tobler LH, Rehermann B, Busch MP, Edlin BR, Talal AH. Induction of CXCR3- and CCR5-associated chemokines during acute hepatitis C virus infection. J Hepatol 2011;55(3):545-53.

6. Bekker V, Chanock SJ, Yeager M, Hutchinson AA, von Hahn T, Chen S, Xiao N, Dotrang M, Brown M, Busch MP, Edlin BR, Rice CM, O'Brien TR. Genetic variation in CLDN1 and susceptibility to hepatitis C virus infection. J Viral Hepat 2010; 17:192-200.
7. Zeremski M, Shu MA, Brown Q, Wu Y, Des Jarlais D, Busch MP, Talal AH, Edlin BR. HCV-specific T-cell immune responses in seronegative injection drug users. J Viral Hepat 2009;16:10-20.
8. Backmund M, Schuetz C, Meyer K, Edlin BR, Reimer J. The risk of emergency room treatment due to overdose in injection drug users. J Addict Dis 2009;28:68-73.
9. Mizukoshi E, Eisenbach C, Edlin BR, Newton KP, Raghuraman S, Weiler-Normann C, Tobler LH, Busch MP, Carrington M, McKeating JA, O'Brien TR, Rehermann B. Hepatitis C virus-specific immune responses of frequently exposed long-term injection drug users. J Infect Dis 2008;198:203-12.
10. Tseng FC, Edlin BR, Zhang M, Kral A, Busch MP, Ortiz-Conde BA, Welzel TM, O'Brien TR. The inverse relationship between chronic HBV and HCV infections among injection drug users is associated with decades of age and drug use. J Viral Hepat 2008; 15(9):690-8.
11. Weiss JJ, Bhatti L, Dieterich DT, Edlin BR, Fishbein DA, Goetz MB, Yu K, Wagner GJ. Hepatitis C patients' self-reported adherence to pegylated interferon and ribavirin. Aliment Pharmacol Ther 2008; 28:289-93.
12. Brown EE, Zhang M, Zarin-Pass R, Bernig T, Tseng FC, Xiao N, Yeager M, Edlin BR, Chanock SJ, O'Brien TR. MBL2 and hepatitis C virus infection among injection drug users. BMC Infect Dis 2008;8:57.
13. Page-Shafer K, Pappalardo BL, Tobler LH, Phelps BH, Edlin BR, Moss AR, Wright TL, Wright DJ, O'Brien TR, Caglioti S, Busch MP. Testing strategy to identify cases of acute hepatitis C virus (HCV) infection and project HCV incidence rates. J Clin Microbiol 2008;46(2);499-506.
14. Kuntzen T, Timm J, Berical A, Lennon N, Berlin AM, Young S, Lee B, Heckerman D, Carlson J, Reyor L, Kleyman M, McMahon CM, Birch C, Schulze zur Wiesch JC, Ledlie T, Koehrsen M, Kodira C, Roberts AD, Lauer GM, Rosen HR, Bihl FK, Cerny A, Spengler U, Liu Z, Kim AY, Xing Y, Schneidewind A, Madey MA, Fleckenstein JF, Park VM, Galagan JE, Nusbaum C, Walker BD, Lake-Bakaar GV, Daar ES, Jacobson IM, Gomperts ED, Edlin BR, Donfield SM, Chung RT, Talal AH, Marion TN, Birren BW, Henn MR, Allen TM. Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naïve patients. Hepatology 2008;48(6):1769-78.
15. Bacchetti P, Tien PC, Seaberg EC, O'Brien TR, Augenbraun MH, Busch MP, Edlin BR. Estimating past hepatitis C infection risk from reported risk factor histories: implications for imputing age of infection and modeling fibrosis progression. BMC Infect Dis 2007;7:145.
16. Tseng FC, O'Brien TR, Zhang M, Kral A, Ortiz-Conde BA, Busch MP, Edlin BR. Seroprevalence of hepatitis B and C viruses among San Francisco Bay area injection drug users, 1998-2000. Hepatology 2007:46(3):666-71.
17. Bluthenthal RN, Do DP, Finch BK, Martinez A, Edlin BR, Kral AH. Community characteristics associated with HIV risk among injection drug users in the San Francisco Bay Area: A multi-level analysis. J Urban Health 2007;84(5):653-66.
18. Bourgois P, Martinez A, Kral A, Edlin BR, Schonberg J, Ciccarone D. Reinterpreting ethnic patterns among white and African American men who inject heroin: A social science of medicine approach. PLoS Med 2006; 3(10):1805-15(e452).
19. Gonzalez S, Liu R-C, Edlin BR, Jacobson IM, Talal AH. Human immunodeficiency-virus hepatitis C virus-coinfected patients with normal alanine aminotransferase levels. J Acquir Immune Defic Syndr 2006;41(5):582-9.
20. Jacobson IM, Gonzalez SA, Ahmed F, Lebovics E, Min AD, Bodenheimer HC Jr, Esposito SP, Brown RS Jr, Bräu N, Klion FM, Tobias H, Bini EJ, Brodsky N, Cerulli MA, Aytaman A, Gardner PW, Geders JM, Spivack JE, Rahmin MG, Berman DH, Ehrlich J, Russo MW, Chait M, Rovner D, Edlin BR. A randomized trial of pegylated interferon alfa-2b plus ribavirin in the retreatment of chronic hepatitis C. Am J Gastroenterol 2005;100(11):2453-62.
21. Seal KH, Thawley R, Gee L, Bamberger J, Kral AH, Ciccarone D, Downing M, Edlin BR. Providing naloxone and resuscitation training to injection drug users to prevent heroin overdose death. J Urban Health 2005;82(2):303-11.
22. Downing M, Riess TH, Vernon K, Mulia N, Hollinquest M, McKnight C, Des Jarlais DC, Edlin BR. It takes a community: successful implementation of syringe exchange programs. AIDS Educ Prev 2005; 17(1):68-78.
23. Kral AH, Lorvick J, Ciccarone D, Wenger L, Gee L, Martinez A, Edlin BR. HIV prevalence and risk behaviors among men who have sex with men and inject drugs in San Francisco. J Urban Health 2005;82(1 Suppl 1):i43-50.
24. Backmund M, Meyer K, Edlin BR. Infrequent reinfection after successful treatment for hepatitis C virus infection in injection drug users. Clin Infect Dis 2004;39:1540-3.
25. Tsui R, Herring BL, Barbour JD, Grant RM, Bacchetti P, Kral A, Edlin BR, Delwart EL. Human immunodeficiency virus type 1 superinfection was not detected following 215 years of injection drug user exposure. J Virol 2004;78:94-103.
26. Tanaka Y, Pfeiffer R, Yeo AE, Mizokami M, Edlin BR, Castle P, O'Brien TR, Alter HJ, Shih JW-K. PCR-probe capture hybridization assay and statistical model for SEN virus prevalence estimation. J Med Virol 2004;73(1):123-30.
27. Charlebois ED, Perdreau-Remington F, Kreiswirth B, Bangsberg DR, Ciccarone D, Ng VL, Chansky K, Edlin BR, Chambers HF. Origins of community strains of methicillin-resistant Staphylococcus aureus. Clin Infect Dis 2004;39:47-54.
28. Canchis PW, Yee HT, Fiel MI, Davila J, Dieterich DT, Liu R-C, Chiriboga L, Jacobson IM, Edlin BR, Talal AH. Intrahepatic CD4 cell depletion and apoptosis in hepatitis C virus/HIV#150;Coinfected patients. J Acquir Immune Defic Syndr 2004;37:1125-31.
29. McFarland W, Page-Shafer K, Edlin BR, Kellogg T, Riley E, Gee L, Moss A, Busch M, Klausner JD, Dilley J. Persistent HIV incidence among injection drug users in San Francisco during the 1990s: results of five studies. J Acquir Immune Defic Syndr 2004;37(5):1667-9.
30. Canchis PW, Gonzalez SA, Fiel MI, Chiriboga L, Yee H, Edlin BR, Jacobson IM, Talal AH. Hepatocyte proliferation in chronic hepatitis C: correlation with degree of liver disease and serum alpha-fetoprotein. Liver 2004;24:198-203.
31. Pfeiffer R, Tanaka Y, Yeo AE, Umemura T, Seal KH, Shih JW, Alter HJ, Edlin BR, O'Brien TR. Prevalence of SEN viruses among injection drug users in the San Francisco Bay area. J Infect Dis 2003;188:13-8.
32. Seal KH, Kral AH, Lorvick J, McNees A, Gee L, Edlin BR. A randomized controlled trial of monetary incentives vs. outreach to enhance adherence to the hepatitis B vaccine series among injection drug users. Drug Alcohol Depend 2003;71:127-31.
33. Cannon MJ, Dollard SC, Black JP, Edlin BR, Hannah C, Hogan SE, Patel MM, Jaffe HW, Offermann MK, Spira TJ, Pellett PE, Gunthel CJ. Risk factors for Kaposi's sarcoma in men seropositive for both human herpesvirus 8 and human immunodeficiency virus. AIDS 2003; 17:215-22.
34. Kral AH, Lorvick J, Gee L, Bacchetti P, Rawal B, Busch M, Edlin BR. Trends in human immunodeficiency virus seroincidence among street-recruited injection drug users in San Francisco, 1987-1998. Am J Epidemiol 2003;157:915-22.
35. Atkinson J, Edlin BR, Engels EA, Seal KH, Kral AH, Whitby D, O'Brien TR. Seroprevalence of human herpesvirus 8 among injection drug users in San Francisco. J Infect Dis 2003;187:974-81.
36. Davidson PJ, McLean RL, Kral AH, Gleghorn AA, Edlin BR, Moss AR. Fatal heroin-related overdose in San Francisco, 1997#150;2000: a case for targeted intervention. J Urban Health 2003; 80:261-73.
37. Seal KH, Downing M, Kral AH, Singleton-Banks S, Hammond JP, Lorvick J, Ciccarone D, Edlin BR. Attitudes about prescribing take-home naloxone to injection drug users for the management of heroin overdose: a survey of street-recruited injectors in the San FranciscoBay area. J Urban Health 2003; 80:291-301.
38. Snead J, Downing M, Lorvick J, Garcia B, Thawley R, Kegeles S, Edlin BR. Secondary syringe exchange among injection drug users. J Urban Health 2003; 80:330-48.
39. Seal KH, Kral AH, Gee L, Moore LD, Bluthenthal RN, Lorvick J, Edlin BR. Predictors and prevention of nonfatal overdose among street-recruited injection heroin users in the San Francisco Bay Area, 1998-1999. Am J Public Health 2001; 91:1842-6.
40. Burris S, Norland J, Edlin BR. Legal aspects of providing naloxone to heroin users in the United States. Int J Drug Policy 2001; 12:237-48.
41. Kral AH, Bluthenthal RN, Lorvick J, Gee L, Bacchetti P, Edlin BR. Sexual transmission of HIV among injection drug users in San Francisco, USA: risk-factor analysis. Lancet 2001; 357:1397-401.
42. Lorvick J, Kral AH, Seal KH, Gee L, Edlin BR. Prevalence and duration of hepatitis C among injection drug users in San Francisco, Calif. Am J Public Health 2001; 91(1):46-7.
43. Bluthenthal RN, Kral AH, Gee L, Erringer EA, Edlin BR. The effect of syringe exchange use on high-risk injection drug users: a cohort study. AIDS 2000; 14:605-11.
44. Binswanger IA, Kral AH, Bluthenthal RN, Rybold DJ, Edlin BR. Abscesses and cellulitis among injection drug users in San Francisco. Clin Infect Dis 2000; 30:579-81.
45. Shafer RW, Edlin BR. Tuberculosis in persons infected with the human immunodeficiency virus: perspective on the past decade. Clin Infect Dis 1996; 22(4):683-704.
46. Edlin BR, Irwin KL, Faruque S, McCoy CB, Word C, Serrano Y, Inciardi JA, Bowser BP, Schilling RF, Holmberg SD, Multicenter Crack Cocaine and HIV Infection Study Team. Intersecting epidemics: crack cocaine use and HIV infection among inner-city young adults. N Engl J Med 1994; 331(21):1422-7.
47. Fitzgibbon JE, Gaur S, Frenkel LD, Laraque F, Edlin BR, Dubin DT. Transmission from one child to another of human immunodeficiency virus type 1 with a zidovudine-resistance mutation. N Engl J Med 1993; 329:1835-41.
48. Edlin BR, Tokars JI, Grieco MH, Crawford JT, Williams J, Sordillo EM, Ong KR, Kilburn JO, Dooley SW, Castro KG, Jarvis WR, Holmberg SD. An outbreak of multidrug-resistant tuberculosis among hospitalized patients with the acquired immunodeficiency syndrome. N Engl J Med 1992; 326:1514-21.
49. Edlin BR, Weinstein RA, Whaling SM, Ou CY, Connolly PJ, Moore JL, Bitran JD. Zidovudine-interferon-alpha combination therapy in patients with advanced HIV-1 infection: biphasic response of p24 antigen and quantitative PCR. J Infect Dis 1992; 165:793-8.
50. Edlin BR, St. Clair MH, Pitha-Rowe PM, Whaling SM, King DM, Bitran JD, Weinstein RA. In vitro resistance to zidovudine and alpha-interferon in HIV-1 isolates from patients: correlations with treatment duration and response. Ann Intern Med 1992; 117(6):457-60.

Selected review articles and editorials:

1. Edlin BR. Test and treat this silent killer [invited commentary]. Nature 2011;474:S18-19.
2. Jacobson IM, Wang S, Edlin BR, Smith VK, Chow EA. Transforming strategies to provide access to care. J Fam Pract 2010;59:(4 Suppl):S59-64.
3. Heffelfinger JD, Patel P, Brooks JT, Calvet H, Daley CL, Dean HD, Edlin BR, Gensheimer KF, Jereb J, Kent CK, Lennox JL, Louie JK, Lynfield R, Peters PJ, Pinckney L, Spradling P, Voetsch AC, Fiore A. Pandemic influenza: implications for programs for controlling HIV infection, tuberculosis, and chronic viral hepatitis. Am J Public Health 2009;99(S2):S333-9.
4. Edlin BR, Carden MR, Ferrando SJ. Managing hepatitis C in users of illicit drugs. Curr Hepatitis Rep 2007;6:60-67.
5. Edlin BR, Carden MR. Injection drug users: the overlooked core of the hepatitis C epidemic [editorial commentary]. Clin Infect Dis 2006;42(5):673-6.
6. Edlin BR, Kresina TF, Raymond DB, Carden MR, GourevitchMN, Rich JD, Cheever LW, CargillVA. Overcoming barriers to prevention, care, and treatment of hepatitis C in illicit drug users [review]. Clin Infect Dis 2005;40(Suppl 5):S276-85.
7. Edlin BR. Hepatitis C prevention and treatment for substance users in the United States: acknowledging the elephant in the living room [commentary]. Int J Drug Policy 2004;15(2):81-91.
8. Edlin BR. Hepatitis C prevention and treatment for injection drug users [NIH Consensus Development Conference address]. Hepatology 2002; 36(5 Suppl 1):S210-9.
9. Edlin BR, Seal KH, Lorvick J, Kral AH, Ciccarone DH, Moore LD, Lo B. Is it justifiable to withhold treatment for hepatitis C from illicit-drug users? [Sounding board] N Engl J Med 2001; 345:211-4.